Dextromethorphan

ROMPE PECHITO ®, New Product With Natural Extracts for Children’s Cough Relief

Retrieved on: 
Wednesday, October 25, 2023
Health, Consumer, Other Health, Children, General Health, Pharmaceutical, Hispanic, Honey, FDA, Temperature, Dextromethorphan, Food, Cough, Common, Laboratory, DM, Mucus, Multimedia, Immune system, Rompe, Pharmacy, Guaifenesin, Food and Drug Administration, Pharmaceutical industry, Dietary supplement

Recently Efficient Laboratories, a Puerto Rican company dedicated to the distribution of its own health care brands, launched a new product, ROMPE PECHITO ®, an over-the-counter medicine for children to relieve cold symptoms.

Key Points: 
  • Recently Efficient Laboratories, a Puerto Rican company dedicated to the distribution of its own health care brands, launched a new product, ROMPE PECHITO ®, an over-the-counter medicine for children to relieve cold symptoms.
  • View the full release here: https://www.businesswire.com/news/home/20231025483780/en/
    Rompe Pechitos® DM is the newest addition to our Rompe Pecho® family.
  • This product is based on a natural ingredient formula with honey and elderberry extract that has proven effective in treating symptoms associated with colds.
  • It is recommended to consult a doctor or pharmacist if you have any questions, and use the product as directed.

'Nature's own Ozempic' or berberine is all over social media. But does it really help you lose weight?

Retrieved on: 
Friday, June 2, 2023
Blood pressure, Exercise, Semaglutide, Systematic review, Science, Insulin, Berberine, Placenta, Diet, Internet celebrity, Pharmacy, Fetus, Codeine, Infection, Sleep, Weight loss, Constipation, Woman, Diarrhea, Uterus, Plant, Waist, Morphine, Dextromethorphan, Overweight, Body mass index, WHO, BMI, Health, Relaxation, Human, Breast milk, Medicinal plants, Dietary supplement, Birth control, Fast food

It’s the herbal preparation berberine.

Key Points: 
  • It’s the herbal preparation berberine.
  • Influencers have been enthusiastically claiming its success in helping them lose weight, with their posts viewed by millions.
  • Does it help people lose weight?

Why berberine? What is it anyway?

    • That includes the high-profile prescription medicine Ozempic, a diabetes drug that also leads to weight loss.
    • Berberine is a bitter tasting chemical extracted from the roots of plants, such as goldenseal and barberry.
    • Berberine extracts have been used in traditional medicines for disorders of the gut and to treat infections.

Is it the same as Ozempic?

    • Ozempic is the brand name of the drug semaglutide, which is used to treat people with type 2 diabetes.
    • More recently, Ozempic has been shown to be effective for weight loss in people who are overweight or obese.
    • Read more:
      Ozempic helps weight loss by making you feel full.

Does berberine help you lose weight?

    • The strongest evidence we have comes from two meta-analyses, types of studies that pool together and analyse the results of other studies.
    • These show that taking a 300-3,000mg berberine a day orally is associated with modest reductions in body mass index (BMI), waist circumference and body weight (around 3kg).
    • We also don’t yet have the data to say what happens when people stop taking berberine.
    • We don’t exactly know how berberine works to help people lose weight.

Is berberine safe?

    • Just because berberine is sold over the counter, doesn’t mean it’s safe.
    • Berberine is not recommended for people who are pregnant as it is thought it can cross the placenta and may harm the fetus.
    • Berberine can also interact with many other drugs and supplements.

So what do do?

    • However, before buying berberine, discuss it with your doctor or pharmacist to see if it will be safe for you, or if other medications might be more appropriate.
    • Associate Professor Tina Hinton has previously received funding from the Schizophrenia Research Institute (formerly Neuroscience Institute of Schizophrenia and Allied Disorders).

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
IHL, Clarion, Benzodiazepine, California Institute for Regenerative Medicine, Johns Hopkins School of Medicine, California Institute of Integral Studies, Caffeine, Psychedelic drug, Johns Hopkins University, Patient, Principal, Psilocybin, Emergency medicine, GHB, Principal investigator, Research, Private practice, Certification, Terminal, Cocaine, Psychedelic therapy, The MINDS Foundation, Psychiatry, Cannabis, Addiction, MDA, DPT, NIH, PTSD, Depression, Sunstone, DSM-IV codes, LSD, Alcoholism, Advisory board, Ketamine, Johns Hopkins Center for Health Security, Behavioural sciences, Johns Hopkins, Economics, Yoga, Methamphetamine, ASX, Consciousness, Trust, CQD, Dextromethorphan, Medical director, Episode, MDMA, Pharmaceutical industry, Nursing

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

Sternal Closure Systems Market worth $2.9 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, November 18, 2022
Growth, Dextromethorphan, Degenerative disease, USD, Hospital, Median sternotomy, Medical device, Airline

CHICAGO, Nov. 18, 2022 /PRNewswire/ -- Sternal Closure Systems Market is projected to reach USD 2.9 billion by 2027 from USD 2.3 billion in 2022, at a CAGR of 5.1% during the forecast period.according to a new report by MarketsandMarkets.The rising adoption of advanced technology drives the sternal closure systems market for sternotomy procedures and favourable medical reimbursement across major markets.

Key Points: 
  • CHICAGO, Nov. 18, 2022 /PRNewswire/ -- Sternal Closure Systems Market is projected to reach USD 2.9 billion by 2027 from USD 2.3 billion in 2022, at a CAGR of 5.1% during the forecast period.according to a new report by MarketsandMarkets.The rising adoption of advanced technology drives the sternal closure systems market for sternotomy procedures and favourable medical reimbursement across major markets.
  • Increasing research activities for sternal closure procedures, emerging markets, and growth in the number of hospitals & surgical centers are expected to provide lucrative growth opportunities for the sternal closure systems market.
  • The closure devices accounted for the largest share of the sternal closure systems market, by product segment, in 2021
    The global sternal closure systems market is segmented into closure devices and bone cement based on product.
  • In 2021, closure devices accounted for the largest share of the global sternal closure systems market.

Sternal Closure Systems Market worth $2.9 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, November 18, 2022
Growth, Dextromethorphan, Degenerative disease, USD, Hospital, Median sternotomy, Medical device, Airline

CHICAGO, Nov. 18, 2022 /PRNewswire/ -- Sternal Closure Systems Market is projected to reach USD 2.9 billion by 2027 from USD 2.3 billion in 2022, at a CAGR of 5.1% during the forecast period.according to a new report by MarketsandMarkets.The rising adoption of advanced technology drives the sternal closure systems market for sternotomy procedures and favourable medical reimbursement across major markets.

Key Points: 
  • CHICAGO, Nov. 18, 2022 /PRNewswire/ -- Sternal Closure Systems Market is projected to reach USD 2.9 billion by 2027 from USD 2.3 billion in 2022, at a CAGR of 5.1% during the forecast period.according to a new report by MarketsandMarkets.The rising adoption of advanced technology drives the sternal closure systems market for sternotomy procedures and favourable medical reimbursement across major markets.
  • Increasing research activities for sternal closure procedures, emerging markets, and growth in the number of hospitals & surgical centers are expected to provide lucrative growth opportunities for the sternal closure systems market.
  • The closure devices accounted for the largest share of the sternal closure systems market, by product segment, in 2021
    The global sternal closure systems market is segmented into closure devices and bone cement based on product.
  • In 2021, closure devices accounted for the largest share of the global sternal closure systems market.

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Retrieved on: 
Thursday, October 27, 2022
Boxed warning, Nasdaq MarketSite, Narcolepsy, Company, CNS, OSA, Dopamine, MD, NASDAQ, Depression, Wakefulness, Breakthrough therapy, Food, Physician, EDS, Excessive daytime sleepiness, Food and Drug Administration, NMDA, Schedule, Dextromethorphan, Hydrogen chloride, MDD, Patient, Bupropion, Adult, Research, GLOBE, Nasdaq, Obstructive sleep apnea, Therapy, FDA, HBR, Times Square, CYP2D6, Medication, Migraine, Central nervous system, Pharmaceutical industry, Solriamfetol, COVID-19

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsomes Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY in the United States by prescription.

Key Points: 
  • NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsomes Chief Executive Officer, the rest of the management team, along with other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Thursday, October 27, 2022, to commemorate the availability of AUVELITY in the United States by prescription.
  • We are honored to ring NASDAQs opening bell to commemorate the availability of Auvelity by prescription and the hard work and dedication of the Axsome team which made it possible.
  • The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, NY.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Retrieved on: 
Thursday, September 8, 2022
Neurodegeneration, Mortality, Technology, Safety, Passive-aggressive behavior, Research, Central nervous system, Therapy, Migraine, CMAI, NASDAQ, Food and Drug Administration, Norepinephrine, Bupropion, Food, Distress, Physician, Agitation, Patent, GLOBE, Breakthrough therapy, Company, FDA, Dementia, AD, Dextromethorphan, CNS, NMDA, Patient, Pharmaceutical industry, COVID-19, Solriamfetol

ADVANCE-2 (Addressing Dementia via Agitation-Centered Evaluation-2) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, trial to assess the efficacy and safety of AXS-05 for the treatment of agitation associated with AD.

Key Points: 
  • ADVANCE-2 (Addressing Dementia via Agitation-Centered Evaluation-2) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, trial to assess the efficacy and safety of AXS-05 for the treatment of agitation associated with AD.
  • AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of Alzheimer's disease agitation.
  • Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation.
  • AXS-05 has been granted FDA Breakthrough Therapy designation for the treatment of Alzheimers disease agitation.

Major Depressive Disorder Market Research Report 2022: Insight, Epidemiology and Market Forecast 2019-2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Pharmaceutical, Health, Mental Health, CNS, US FDA, Lists of diseases, Population, Manic, LY03005, Therapy, Attention, Schizophrenia, Comprehension, Technology, SAGE, AbbVie, Cariprazine, NMDA, Bupropion, Electroconvulsive therapy, Gaps, Clinical trial, Physician, ECT, News, Lists of people executed in the United States, Pharmacodynamics, Psychotherapy, Dextromethorphan, Norepinephrine, D3, Patient, Adult, SME, Disorder, Major depressive disorder, D2, MDD, Bipolar I disorder, Pharmaceutical industry, Medical device, Epidemiology

The "Major Depressive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Major Depressive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Major Depressive Disorder (MDD) - Market Insights, Epidemiology, and Market Forecast - 2032' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of major depressive disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The drug chapter segment of the major depressive disorder (MDD) report encloses the detailed analysis of major depressive disorder (MDD) marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs.
  • Their opinion helps understand and validate current and emerging therapy treatment patterns or major depressive disorder (MDD) market trends.

Painful Sore Throats Meet Their Match - Mucinex® Introduces Mucinex InstaSoothe, a New Line of Lozenges and Spray to Help Fight Against Sore Throat Pain and Irritation

Retrieved on: 
Monday, November 1, 2021
Honey, Public opinion, Head, Enfamil, MD, Dextromethorphan, Guaifenesin, ENT, Sore throat, Cough, Association, CA, Ibuprofen brand names, Amazon, Partnership, Target, Marketing, Veet, American Association for Public Opinion Research, AAPOR, Otorhinolaryngology, Reckitt, Echinacea, Fever, Menthol, RB, Migraine, Air Wick, OnePoll, Walmart, OTC, Multimedia, Irritation, ESOMAR, Market Research Society, Benzocaine, Pain, Research, JAMA Otolaryngology–Head & Neck Surgery, American Association, Clearasil, CVS, Numb, Lysol, European Society of Anaesthesiology and Intensive Care, Opinion, Mouth, Glass wool, Grocery store

Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges: Clinically proven to numb pain fast, Mucinex InstaSoothe Sore Throat + Cough Relief Lozengesare made with active ingredients Hexylresorcinol and Dextromethorphan HBr to quiet cough, provide cooling comfort, and relieve sore throat pain for up to two hours.

Key Points: 
  • Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges: Clinically proven to numb pain fast, Mucinex InstaSoothe Sore Throat + Cough Relief Lozengesare made with active ingredients Hexylresorcinol and Dextromethorphan HBr to quiet cough, provide cooling comfort, and relieve sore throat pain for up to two hours.
  • Mucinex InstaSoothe Sore Throat + Pain Relief Spray:With two powerful pain relievers, Benzocaine and Menthol, the Mucinex InstaSoothe Sore Throat + Pain Relief Spray temporarily relieves pain to soothe the throat.
  • "What separates Mucinex InstaSoothe lozenges from others is that they're clinically proven to numb sore throat pain fast."
  • For those needing relief from a sore throat and cough, the Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges also contain the active ingredient Dextromethorphan HBr to provide cough suppression."

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

Retrieved on: 
Monday, August 23, 2021
Bupropion, National Survey on Drug Use and Health, Company, National, NMDA, Fools and Worthless Liars, CNS, GLOBE, Disability, Physician, Mental health service, Research, World Health Organization, Migraine, PDUFA, Substance Abuse and Mental Health Services Administration, Food, Therapy, Central nervous system, Suicide, Norepinephrine, Breakthrough therapy, NDA, Lists of diseases, MDD, World, Review, Clinical trial, NASDAQ, WHO, Food and Drug Administration, Patient, Guilt, Depression, ASCEND, Pleasure, Dextromethorphan, FDA, GEMINI, Prescription Drug User Fee Act, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

According to the National Institutes of Health, an estimated 7% of U.S. adults, or approximately 19 million, experience MDD each year1.

Key Points: 
  • According to the National Institutes of Health, an estimated 7% of U.S. adults, or approximately 19 million, experience MDD each year1.
  • AXS-05 (dextromethorphan-bupropion) is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of major depressive disorder and other central nervous system (CNS) disorders.
  • A new drug application (NDA) for AXS-05 for the treatment of major depressive disorder is under review by the FDA.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options.